Abstract Background Neoadjuvant therapy miss to mrs cookie improves recurrence-free survival (RFS) in resectable stage III cutaneous melanoma.However, accurately predicting individual recurrence risk remains a significant challenge.We investigated circulating tumour DNA (ctDNA) as a biomarker for recurrence in measurable stage IIIB/C melanoma patients undergoing neoadjuvant immunotherapy.Methods Plasma samples were collected pre-neoadjuvant treatment, pre-surgery and/or six weeks post-surgery from 40 patients enrolled in the OpACIN-neo and PRADO clinical trials.
Patients received two cycles of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) before surgery.Cell free DNA (cfDNA) underwent unbiased pre-amplification followed by tumour-informed mutation detection using droplet digital polymerase chain reaction (ddPCR) with the Bio-Rad QX600 PCR system.Results Pre-treatment ctDNA was detectable in 19/40 (48%) patients.Among these, 17/19 (89%) zero-converted within six weeks of surgery and none recurred.
Positive ctDNA post-surgery (N = 4), irrespective of pre-treatment ctDNA status, was 100% predictive of recurrence (sensitivity 44%, specificity 100%).Furthermore, ctDNA cleared prior to surgery in 7/9 (78%) patients who did not recur, warranting further investigation into ctDNA-guided surgical management.Conclusion Post-surgery ctDNA positivity redken shades eq dark chocolate and zero-conversion are highly predictive of recurrence, offering a window for personalised modification of adjuvant therapy.